CBT-004 is a novel, preservative-free ophthalmic solution targeting VEGF and PDGF receptors to treat vascularized pinguecula. Phase 2 trial results showed significant improvements in conjunctival ...
Credit: Alcon. The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors. Tryptyr significantly improved tear production compared with ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ...
(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...
BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company ...
Dexamethasone sodium phosphate 0.1%; oph soln; contains benzalkonium chloride. Initial therapy: 1 or 2 drops in conjunctival sac every hour during the day and every two hours during the night. When ...
Ace Therapeutics announces its preclinical ophthalmic drug development services to help expedite the discovery of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. IOP decreased with the use of VVN539 in a phase 2 study.
BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Timolol Maleate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results